vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and PEOPLES BANCORP OF NORTH CAROLINA INC (PEBK). Click either name above to swap in a different company.
PEOPLES BANCORP OF NORTH CAROLINA INC is the larger business by last-quarter revenue ($21.5M vs $16.1M, roughly 1.3× Journey Medical Corp). PEOPLES BANCORP OF NORTH CAROLINA INC runs the higher net margin — 30.8% vs -7.8%, a 38.6% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 5.6%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 4.2%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
PEOPLES BANCORP OF NORTH CAROLINA INC is a regional bank holding company headquartered in North Carolina, U.S. It offers a full suite of personal and commercial banking services including deposit accounts, consumer and business loans, mortgage services, and wealth management solutions, primarily serving local residents, small and medium-sized enterprises, and community organizations across its operating areas in North Carolina.
DERM vs PEBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $21.5M |
| Net Profit | $-1.2M | $6.6M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 40.7% |
| Net Margin | -7.8% | 30.8% |
| Revenue YoY | 27.3% | 5.6% |
| Net Profit YoY | -182.0% | 86.4% |
| EPS (diluted) | $-0.04 | $1.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $21.5M | ||
| Q3 25 | $17.0M | $21.4M | ||
| Q2 25 | $15.0M | $20.7M | ||
| Q1 25 | $13.1M | $20.0M | ||
| Q4 24 | $12.6M | $20.4M | ||
| Q3 24 | $14.6M | $20.5M | ||
| Q2 24 | $14.9M | $20.1M | ||
| Q1 24 | $13.0M | $19.8M |
| Q4 25 | $-1.2M | $6.6M | ||
| Q3 25 | $-2.3M | $3.7M | ||
| Q2 25 | $-3.8M | $5.2M | ||
| Q1 25 | $-4.1M | $4.3M | ||
| Q4 24 | $1.5M | $3.6M | ||
| Q3 24 | $-2.4M | $4.0M | ||
| Q2 24 | $-3.4M | $4.9M | ||
| Q1 24 | $-10.4M | $3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 40.7% | ||
| Q3 25 | -9.0% | 22.4% | ||
| Q2 25 | -19.2% | 32.2% | ||
| Q1 25 | -25.3% | 28.2% | ||
| Q4 24 | 17.7% | 22.5% | ||
| Q3 24 | -19.8% | 26.0% | ||
| Q2 24 | -19.7% | 31.3% | ||
| Q1 24 | -77.4% | 23.9% |
| Q4 25 | -7.8% | 30.8% | ||
| Q3 25 | -13.6% | 17.2% | ||
| Q2 25 | -25.3% | 24.9% | ||
| Q1 25 | -31.0% | 21.8% | ||
| Q4 24 | 12.1% | 17.5% | ||
| Q3 24 | -16.3% | 19.3% | ||
| Q2 24 | -22.6% | 24.4% | ||
| Q1 24 | -80.1% | 19.9% |
| Q4 25 | $-0.04 | $1.21 | ||
| Q3 25 | $-0.09 | $0.67 | ||
| Q2 25 | $-0.16 | $0.95 | ||
| Q1 25 | $-0.18 | $0.79 | ||
| Q4 24 | $0.10 | $0.65 | ||
| Q3 24 | $-0.12 | $0.72 | ||
| Q2 24 | $-0.17 | $0.89 | ||
| Q1 24 | $-0.53 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $58.1M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $157.1M |
| Total Assets | $94.6M | $1.7B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $58.1M | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | $59.3M | ||
| Q3 24 | $22.5M | $73.2M | ||
| Q2 24 | $23.9M | — | ||
| Q1 24 | $24.1M | — |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $157.1M | ||
| Q3 25 | $25.9M | $149.5M | ||
| Q2 25 | $19.2M | $144.0M | ||
| Q1 25 | $21.5M | $138.5M | ||
| Q4 24 | $20.1M | $130.6M | ||
| Q3 24 | $10.9M | $136.3M | ||
| Q2 24 | $11.3M | $124.3M | ||
| Q1 24 | $13.0M | $121.1M |
| Q4 25 | $94.6M | $1.7B | ||
| Q3 25 | $85.2M | $1.7B | ||
| Q2 25 | $81.2M | $1.7B | ||
| Q1 25 | $85.0M | $1.7B | ||
| Q4 24 | $80.2M | $1.7B | ||
| Q3 24 | $64.0M | $1.7B | ||
| Q2 24 | $65.2M | $1.7B | ||
| Q1 24 | $66.6M | $1.7B |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $21.4M |
| Free Cash FlowOCF − Capex | — | $20.0M |
| FCF MarginFCF / Revenue | — | 92.7% |
| Capex IntensityCapex / Revenue | — | 6.6% |
| Cash ConversionOCF / Net Profit | — | 3.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $34.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $21.4M | ||
| Q3 25 | $-2.4M | $4.7M | ||
| Q2 25 | $-942.0K | $5.5M | ||
| Q1 25 | $-2.8M | $5.9M | ||
| Q4 24 | $2.2M | $20.6M | ||
| Q3 24 | $-1.2M | $4.9M | ||
| Q2 24 | $-5.2M | $6.7M | ||
| Q1 24 | $-5.0M | $3.7M |
| Q4 25 | — | $20.0M | ||
| Q3 25 | — | $4.4M | ||
| Q2 25 | — | $5.4M | ||
| Q1 25 | — | $5.2M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $6.6M | ||
| Q1 24 | — | $3.5M |
| Q4 25 | — | 92.7% | ||
| Q3 25 | — | 20.4% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | 25.8% | ||
| Q4 24 | — | 98.0% | ||
| Q3 24 | — | 22.9% | ||
| Q2 24 | — | 32.7% | ||
| Q1 24 | — | 17.9% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 2.9% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | 3.22× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 1.36× | ||
| Q4 24 | 1.46× | 5.78× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 0.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
PEBK
Segment breakdown not available.
